RepligenRGEN
About: Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Employees: 1,783
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
34% more call options, than puts
Call options by funds: $55M | Put options by funds: $40.9M
15% more capital invested
Capital invested by funds: $7.15B [Q2] → $8.21B (+$1.06B) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 152 | Existing positions reduced: 152
2.89% less ownership
Funds ownership: 101.57% [Q2] → 98.69% (-2.89%) [Q3]
4% less funds holding
Funds holding: 451 [Q2] → 432 (-19) [Q3]
21% less first-time investments, than exits
New positions opened: 73 | Existing positions closed: 92
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
RBC Capital Conor McNamara 34% 1-year accuracy 14 / 41 met price target | 64%upside $205 | Outperform Reiterated | 26 Sept 2024 |
Wells Fargo Brandon Couillard 24% 1-year accuracy 4 / 17 met price target | 44%upside $180 | Overweight Initiated | 27 Aug 2024 |
Financial journalist opinion
Based on 7 articles about RGEN published over the past 30 days
